Imprimis Epinephrine-Lidocaine Vials Recall: Lack of Sterility Risk
Imprimis recalls specific epinephrine-lidocaine vials for intraocular use due to lack of sterility assurance. Affected vials have unique lot numbers and expiration dates. Consumers should contact the manufacturer for details.
Recall notice
Lack of Assurance of Sterility
Contact the company
What happened, in plain English
Imprimis has recalled certain epinephrine-lidocaine vials for eye injections because they may not be sterile. This could lead to infections if used improperly. The recall affects specific lot numbers with expiration dates listed in the notice. Read more at govinfonow.com/recall/32674-imprimis-epinephrine-lidocaine-vials-recall-lack-of-sterility-risk.
Source Summary by GovInfoNow · govinfonow.com/recall/32674-imprimis-epinephrine-lidocaine-vials-recall-lack-of-sterility-risk · Updated September 23, 2026 · FDA enforcement record: FDA #D-0519-2024
Cite this page
“Imprimis Epinephrine-Lidocaine Vials Recall: Lack of Sterility Risk.” GovInfoNow, updated September 23, 2026. https://govinfonow.com/recall/32674-imprimis-epinephrine-lidocaine-vials-recall-lack-of-sterility-risk. Based on FDA recall #D-0519-2024 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0519-2024%22&limit=1).
Why it’s dangerous
The vials lack assurance of sterility, meaning they might not be clean enough for eye injections. If used, this could cause infections or other complications in the eye. The risk is not clearly described in terms of how serious it is or how likely it is to happen.
Who’s affected
People who own or use these vials for eye injections are affected. Those with the specific lot numbers and expiration dates listed in the recall are most at risk.
How to tell if you have this one
Check the vial label for the lot number and expiration date. The affected vials have specific lot numbers like 23JUL025, 23SEP012, and others listed in the recall notice.
- Brand
Imprimis- Category
Drug
What to do — step by step
Contact Manufacturer
Reach out to Imprimis NJOF, LLC at 1705 Route 46 West, unit 6B, Ledgewood, NJ 07852 for specific instructions on handling the recalled vials.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide within the United States” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA published this recall 22 days after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
Dates from the agency record only; steps without a date are left out.
Questions people ask
What lot numbers are affected?
Affected lot numbers include 23JUL025, 23SEP012, 23OCT015, 23OCT020, 23OCT026, 23NOV030, 23DEC026, 24JAN011, 24FEB033, and 24JAN050.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0519-2024 (May 14, 2024) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0519-2024 to see it in context.
- Plain-language summary written by qwen3:4b on September 23, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.